On August 2, the United States Food and Drug Administration (FDA) approved the drug ibrutinib for treatment of adults with chronic graft versus host disease (cGVHD).
Weill Cornell Bone Marrow Transplant Program
Weill Cornell Bone Marrow Transplant Program
%d bloggers like this:
